Department of Endocrinology, Harvard Medical School
Dr. Hamdy is the Medical Director of the Obesity Clinical Program, at Joslin Diabetes Center in Boston and Assistant Professor of Medicine at Harvard Medical School. His clinical research focuses on the short- and long-term effects of lifestyle modification on metabolic and cardiovascular risk factors, body fat distribution and inflammation markers in obese individuals with diabetes. He and his colleagues research led to the first discovery that obese adults who lost 7 of their initial weight had significant improvement of their vascular endothelial function. This improvement may eventually prevent progression of atherosclerosis and coronary artery disease. He is a co-investigator of 2 landmark studies; the National Diabetes Prevention Program and the Look AHEAD Action for Health in Diabetes Study. He developed the “Weight Achievement and Intensive Treatment-Why WAIT?” program and the YOU-Turn program, the world’s first clinical practice weight management programs for obese patients with diabetes. Why WAIT showed long-term significant improvement in diabetes control, lipid, kidney and liver profiles together with significant improvement in quality of life and physical fitness. Participants were also able to cut their diabetes medications by ~50. He also chaired the task force that developed the Joslin Nutrition Guidelines and is member of the Nutrition Committee of the American Association of Clinical Endocrinologist AACE that developed many of the current guidelines for nutrition and obesity management. He has more than 150 peerreviewed original articles, reviews, chapters, conference abstracts and proceedings. He is on the editorial board of US endocrinology, section editor of the Current diabetes report and is member of the editorial review board of many scentific medical journals including JAMA, Diabetes Care, Obesity Research and the Expert Opinions.
His clinical research focuses on the short- and long-term effects of lifestyle modification on metabolic and cardiovascular risk factors, body fat distribution and inflammation markers in obese individuals with diabetes.